Opinion

Video

Overview of the QUILT Trial in BCG-Unresponsive NMIBC

Author(s):

Gordon A. Brown, DO,Siamak Daneshmand, MD

Jason Hafron, MD, CMO, provides an overview of the QUILT trial investigating N-803 in patients with BCG-unresponsive high-grade non–muscle invasive bladder cancer.

Current Time 0:00
Duration 2:30
Loaded: 0%
Stream Type LIVE
Remaining Time 2:30
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Newsletter

    Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

    Subscribe Now!
    Related Videos
    Anne Schuckman, MD, outlines current challenges in NMIBC care
    Anne Schuckman, MD, outlines current challenges in NMIBC care
    Daniel D. Joyce, MD, MS, answers a question during a Zoom video interview
    Investigators compare trimodal therapy vs cystectomy in MIBC
    Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
    Investigators assess ctDNA’s role in NMIBC
    Urology Times Mitomycin RX Review Square Thumb
    RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practice
    Urology Times Mitomycin RX Review Square Thumb
    RX Review: TURBT vs chemoablation for low-grade, intermediate-risk NMIBC
    Urology Times Mitomycin RX Review Square Thumb
    RX Review: A paradigm shift for low-grade, intermediate-risk NMIBC
    Urology Times Mitomycin RX Review Square Thumb
    RX Review: How mitomycin for intravesical solution works in treating LG-IR-NMIBC
    Urology Times Mitomycin RX Review Square Thumb
    RX Review: Redefining treatment for LG-IR-NMIBC
    Vignesh Packiam, MD, on the MOA, dosing of detalimogene voraplasmid
    Vignesh Packiam, MD, on the MOA, dosing of detalimogene voraplasmid
    Anne Schuckman, MD, highlights promising new developments in NMIBC
    Anne Schuckman, MD, highlights promising new developments in NMIBC
    Related Content
    Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
    July 8th 2025

    UK’s MHRA approves nogapendekin alfa inbakicept plus BCG in NMIBC

    Benjamin P. Saylor Hannah Clarke
    According to the company, the MHRA approval represents the first marketing approval outside the US for NAI.
    medical depiction of bladder cancer
    May 31st 2023

    Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

    Urology Times staff
    In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
    Zelenectide pevedotin plus pembrolizumab shows promising anti-tumor activity in mUC
    July 8th 2025

    Zelenectide pevedotin plus pembrolizumab shows promising anti-tumor activity in mUC

    Hannah Clarke
    The data, collected as part of the phase 1/2 Duravelo-1 trial, showed an objective response rate of 65%.
    Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease
    May 26th 2022

    Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

    Urology Times staff
    “We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.
    Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
    July 4th 2025

    Top 10 Urology Times videos from the first half of 2025

    Urology Times staff
    Catch up on exclusive videos you may have missed from the first half of the year.
    FDA logo
    July 3rd 2025

    FDA news recap in urology for Q2 2025

    Hannah Clarke Benjamin P. Saylor Jason M. Broderick
    Here’s a look back at notable news between April and June 2025.
    © 2025 MJH Life Sciences

    All rights reserved.